Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 8/20 | 0.39 |
| ▸ | PLAU | P00749 | 7/20 | 0.39 |
| ▸ | PLG | P00747 | 5/20 | 0.39 |
| ▸ | TPSB2 | P20231 | 4/20 | 0.39 |
| ▸ | F11 | P03951 | 3/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.39 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.33 |
| ▸ | ICMT | O60725 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23219028 | 1.00 | CFD (0.39) | CFDPLAUPLGTPSB2F11 | |
| SCHEMBL23219209 | 0.95 | CFD (0.40) | CFDPLAUPLGTPSB2F11 | |
| SCHEMBL29853066 | 0.95 | CFD (0.40) | CFDPLAUPLGTPSB2F11 | |
| SCHEMBL29852616 | 0.92 | CFD (0.42) | CFDPLAUPLGTPSB2F11 | |
| SCHEMBL23219138 | 0.92 | CFD (0.42) | CFDPLAUPLGTPSB2F11 | |
| SCHEMBL23219193 | 0.88 | CFD (0.43) | CFDPLAUPLGTPSB2F11 | |
| SCHEMBL29852818 | 0.88 | CFD (0.43) | CFDPLAUPLGTPSB2F11 | |
| SCHEMBL23229178 | 0.84 | CFD (0.37) | CFDPLAUPLGTPSB2F11 | |
| SCHEMBL23228977 | 0.84 | CFD (0.37) | CFDPLAUPLGTPSB2F11 | |
| SCHEMBL23219231 | 0.83 | PLG (0.46) | CFDPLAUPLGTPSB2F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| EP-4041238-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | CFD 1/4885PLAU 1119/4885PLG 421/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | CFD 1/4885PLAU 144/4885PLG 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.